nach oben

Journal of Neuro-Oncology

Erschienen in:

19.04.2018 | Laboratory Investigation

Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma

verfasst von: Dai Kamamoto, Kentaro Ohara, Yohei Kitamura, Kazunari Yoshida, Yutaka Kawakami, Hikaru Sasaki

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC) often shows extracranial metastasis, and treatment options are very limited. Immune-checkpoint molecules have not been studied well in SFT/HPCs, and their role in intracranial SFT/HPCs remains unclear.

Methods

We investigated the expression of programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and tumor-infiltrating lymphocytes (TIL) in 16 patients of intracranial SFT/HPC by immunohistochemistry to determine if correlation with prognosis exists.

Results

Median overall survival (OS) of 16 patients was 9.2 years, and median follow-up of alive patients was 9.9 years. Recurrence was observed in 13 (81.3%) patients, and extracranial metastasis were observed in 6 (37.5%). PD-L1 expression was observed in all 16 tumors, whereas PD-1 expression was observed in 2. CD3 and CD8 expressions were observed in TILs in 12 and 13 patients respectively. Although the ratio of PD-L1 positive-tumor cells was not associated with OS, progression-free survival, or metastasis-free survival (MFS), diffuse staining of PD-L1 showed a trend toward shorter time to treatment failure (TTF: time to either extracranial metastasis or death) (p = 0.072). Similarly, the intense staining of PD-L1 was associated with shorter MFS (p = 0.0084) and TTF (p = 0.033). CD3 or CD8 expression was not associated with any of the prognostic parameters. In the combined analysis of PD-L1 and CD8, diffuse PD-L1 staining coupled with no or sparse CD8 expression was significantly associated with a shorter TTF (p = 0.005) and showed a trend toward shorter MFS (p = 0.0611).

Conclusions

PD-L1 is frequently expressed in intracranial SFT/HPCs, and diffuse or intense PD-L1 expression might be associated with the early occurrence of extracranial metastases.

Louis D, Ohgaki H, Wiestler O, Cavenee WK (2016) WHO classification of tumours of the central nervous system, revised, 3rd edn. IARC, Lyon

Robinson DR, Wu Y-M, Kalyana-Sundaram S et al (2013) Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet 45:180–185. https://doi.org/10.1038/ng.2509 CrossRefPubMedPubMedCentral

Chmielecki J, Crago AM, Rosenberg M et al (2013) Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet 45:131–132. https://doi.org/10.1038/ng.2522 CrossRefPubMedPubMedCentral

Hasegawa T, Matsuno Y, Shimoda T et al (1999) Extrathoracic solitary fibrous tumors: their histological variability and potentially aggressive behavior. Hum Pathol 30:1464–1473. https://doi.org/10.1016/S0046-8177(99)90169-7 CrossRefPubMed

Bouvier C, Met́ellus P, De Paula AM et al (2012) Solitary fibrous tumors and hemangiopericytomas of the meninges: overlapping pathological features and common prognostic factors suggest the same spectrum of tumors. Brain Pathol 22:511–521. https://doi.org/10.1111/j.1750-3639.2011.00552.x CrossRefPubMed

Guthrie BL, Ebersold MJ, Scheithauer BW, Shaw EG (1989) Meningeal hemangiopericytoma: Histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery. https://doi.org/10.1227/00006123-198910000-00003 CrossRefPubMed

Sleijfer S, Ray-Coquard I, Papai Z et al (2009) Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC Study 620). J Clin Oncol 27:3126–3132. https://doi.org/10.1200/JCO.2008.21.3223 CrossRefPubMed

Kasper B, Sleijfer S, Litière S et al (2014) Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: Subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Ann Oncol. https://doi.org/10.1093/annonc/mdt586 PubMedPubMedCentralCrossRef

Lee S, Kim S, Park S et al (2014) Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma. Clin Sarcoma Res 4:13. https://doi.org/10.1186/2045-3329-4-13 CrossRefPubMedPubMedCentral

10.

Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264. https://doi.org/10.1038/nrc3239 CrossRefPubMedPubMedCentral

11.

Lenschow DJ, Walunas TL, Jeffrey A (1996) CD28/B7 system of t cell costimulation. Annu Rev Immunol 14:233–258. https://doi.org/10.1146/annurev.immunol.14.1.233 CrossRefPubMed

12.

Wing K, Onishi Y, Prieto-Martin P et al (2008) CTLA-4 control over Foxp3 + regulatory T cell function. Science 322:271–275. https://doi.org/10.1126/science.1160062 CrossRefPubMed

13.

Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887–3895PubMedPubMedCentralCrossRef

14.

Iwai Y, Ishida M, Tanaka Y et al (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293–12297. https://doi.org/10.1073/pnas.192461099 CrossRefPubMed

15.

Taube JM, Klein A, Brahmer JR et al (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20:5064–5074. https://doi.org/10.1158/1078-0432.CCR-13-3271 CrossRefPubMedPubMedCentral

16.

Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. https://doi.org/10.1056/NEJMoa1003466 PubMedPubMedCentralCrossRef

17.

Mcdermott DF, Atkins MB (2013) PD-1 as a potential target in cancer therapy. Cancer Med 2:662–673. https://doi.org/10.1002/cam4.106 PubMedPubMedCentralCrossRef

18.

Slovin SF, Higano CS, Hamid O et al (2013) Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase i/ii study. Ann Oncol 24:1813–1821. https://doi.org/10.1093/annonc/mdt107 CrossRefPubMedPubMedCentral

19.

Brahmer JR, Tykodi SS, Chow LQM et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465. https://doi.org/10.1056/NEJMoa1200694 CrossRefPubMedPubMedCentral

20.

Wang A, Wang HY, Liu Y et al (2015) The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur J Surg Oncol. https://doi.org/10.1016/j.ejso.2015.01.020 CrossRefPubMed

21.

Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833. https://doi.org/10.1056/NEJMoa1606774 CrossRefPubMed

22.

Brahmer JR, Drake CG, Wollner I et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167–3175. https://doi.org/10.1200/JCO.2009.26.7609 CrossRefPubMedPubMedCentral

23.

Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. https://doi.org/10.1056/NEJMoa1200690 CrossRefPubMedPubMedCentral

24.

Konishi J, Yamazaki K, Azuma M et al (2004) B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 10:5094–5100. https://doi.org/10.1158/1078-0432.ccr-04-0428 CrossRefPubMed

25.

Thompson RH, Gillett MD, Cheville JC et al (2004) Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 101:17174–17179. https://doi.org/10.1073/pnas.0406351101 CrossRefPubMed

26.

Ohigashi Y, Sho M, Yamada Y et al (2005) Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11:2947–2953. https://doi.org/10.1158/1078-0432.CCR-04-1469 CrossRefPubMed

27.

Wu C, Zhu Y, Jiang J et al (2006) Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 108:19–24. https://doi.org/10.1016/j.acthis.2006.01.003 CrossRefPubMed

28.

Hino R, Kabashima K, Kato Y et al (2010) Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116:1757–1766. https://doi.org/10.1002/cncr.24899 CrossRefPubMed

29.

Nakanishi J, Wada Y, Matsumoto K et al (2007) Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 56:1173–1182. https://doi.org/10.1007/s00262-006-0266-z CrossRefPubMed

30.

Movva S, Wen W, Chen W et al (2015) Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets. Oncotarget 6:12234–12247. https://doi.org/10.18632/oncotarget.3498 CrossRefPubMedPubMedCentral

31.

Kleihues P, Burger P, Scheithauer B (1993) Histological typing of tumours of the central nervous system. Springer, Berlin. https://doi.org/10.1007/978-3-642-84988-6 CrossRef

32.

Kleihues P, Cavenee WK (2000) Pathology and genetics of tumours of the nervous system. IARC, Lyon

33.

Louis D, Ohgaki H, Wiestler O, Cavenee WK (2007) WHO classification of tumours of the central nervous system, 4 th edn. IARC, Lyon

34.

Feng Y, Shen J, Gao Y et al (2015) Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma. Oncotarget 6:11139–11149. https://doi.org/10.18632/oncotarget.3576 PubMedPubMedCentralCrossRef

35.

Han SJ, Ahn BJ, Waldron JS et al (2009) Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion. Neuroreport 20:1597–1602. https://doi.org/10.1097/WNR.0b013e32833188f7 CrossRefPubMed

36.

Berghoff AS, Kiesel B, Widhalm G et al (2015) Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol 17:1064–1075. https://doi.org/10.1093/neuonc/nou307 CrossRefPubMed

37.

Horn L, Spigel DR, Gettinger SN, Antonia SJ, Gordon MS, Herbst RS, Sequist LV, Chappey C, Kowanetz M, Sandler A, Soria J-C (2015) Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO)

38.

Spira AI, Park K, Mazières J, Vansteenkiste JF, Rittmeyer A, Ballinger M, Waterkamp D, Kowanetz M, Mokatrin A, Fehrenbacher L (2015) Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO)

39.

Spigel DR, Chaft JE, Gettinger SN, Chao BH, Dirix LY, Schmid P, Chow LQM, Chappey C, Kowanetz M, Sandler A, Fun RP (2015) Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC). 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO)

40.

Nduom EK, Wei J, Yaghi NK et al (2016) PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol 18:195–205. https://doi.org/10.1093/neuonc/nov172 CrossRefPubMed

41.

Velcheti V, Schalper KA, Carvajal DE et al (2014) Programmed death ligand-1 expression in non-small cell lung cancer. Lab Investig 94:107–116. https://doi.org/10.1038/labinvest.2013.130 CrossRefPubMed

42.

Weber J, Hamid O, Amin A et al (2013) Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun 13:7PubMedPubMedCentral

43.

Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639. https://doi.org/10.1056/NEJMoa1507643 CrossRefPubMedPubMedCentral

44.

Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028. https://doi.org/10.1056/NEJMoa1501824 CrossRefPubMed

45.

Iwai Y, Terawaki S, Honjo T (2005) PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 17:133–144. https://doi.org/10.1093/intimm/dxh194 CrossRefPubMed

46.

Murata D, Mineharu Y, Arakawa Y et al (2018) High programmed cell death 1 ligand-1 expression: association with CD8 + T-cell infiltration and poor prognosis in human medulloblastoma. J Neurosurg 128:710–716. https://doi.org/10.3171/2016.11.JNS16991 CrossRefPubMed

47.

Hamanishi J, Mandai M, Iwasaki M et al (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104:3360–3365. https://doi.org/10.1073/pnas.0611533104 CrossRefPubMed

48.

Ogiya R, Niikura N, Kumaki N et al (2016) Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. Cancer Sci 107:1730–1735. https://doi.org/10.1111/cas.13101 CrossRefPubMedPubMedCentral

49.

Durand-Panteix S, Farhat M, Youlyouz-Marfak I et al (2012) B7-H1, Which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels. J Immunol 189:181–190. https://doi.org/10.4049/jimmunol.1102277 CrossRefPubMed

Titel: Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma
verfasst von: Dai Kamamoto
Kentaro Ohara
Yohei Kitamura
Kazunari Yoshida
Yutaka Kawakami
Hikaru Sasaki
Publikationsdatum: 19.04.2018
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2018
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2876-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

GOLPH3 promotes glioma progression via facilitating JAK2–STAT3 pathway activation

Leptomeningeal disease in uveal melanoma: a case series

Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery

Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma

Cranial nerve outcomes after primary stereotactic radiosurgery for symptomatic skull base meningiomas